Mubritinib TCI M3058

TCI M3058 is Mubritinib, CAS 366017-09-6, a small-molecule compound known among researchers as a kinase inhibitor. Mubritinib has been widely studied as an inhibitor of ErbB-family receptor tyrosine kinases, particularly HER2, and in subsequent literature it has also been reported to affect the mitochondrial electron transport chain. In the laboratory, a compound of this kind serves as a pharmacological tool: it is not a therapeutic product but a reagent used to test what happens to cells or enzymes when a signalling pathway is selectively switched off, allowing the function of that pathway to be mapped experimentally.

The characteristics that lead researchers to select Mubritinib are its high potency at low concentrations and its target profile, which is documented in the scientific literature, giving investigators a reference point when designing dose-response curves. As a solid organic compound soluble in solvents such as dimethyl sulfoxide, Mubritinib is easily prepared as a concentrated stock solution and then diluted into culture medium across a working concentration range. Its dual character as both a kinase inhibitor and a disruptor of mitochondrial metabolism also makes it attractive to groups studying more than one mechanism within a single experimental system.

In Indonesian laboratories, a reagent of this type is typically used in university research groups, biomedical research institutes, and cell biology facilities that run signalling and cell-viability studies. It is generally ordered in small quantities appropriate to research-scale work, stored centrally in a shared low-temperature facility, and dispensed as aliquots for individual projects. Because it functions as a reference inhibitor, it is often kept on hand as a comparison compound alongside locally developed or screened candidates.

• Receptor tyrosine kinase inhibition studies: Mubritinib is used to block ErbB-family kinase activity, particularly HER2, so researchers can observe downstream signalling changes that follow selective pathway shutdown in treated cells.
• Mitochondrial electron transport chain research: because later literature reports an effect on the electron transport chain, this compound lets investigators probe cellular energy metabolism within the same experimental system they use for kinase work.
• Dose-response curve construction: its documented target profile and potency at low concentrations give researchers a published reference point when establishing concentration ranges and interpreting inhibition curves in cell-based assays.
• Cell signalling pathway mapping: as a pharmacological tool rather than a therapeutic agent, it allows teams to determine the functional role of a pathway by observing what cells do once that pathway is inhibited.
• Reference inhibitor in comparative screening: research groups keep this well-characterised compound as a benchmark against which newly synthesised or screened candidate inhibitors can be evaluated under identical assay conditions.

Store Mubritinib in its original tightly closed container under the conditions specified on the manufacturer's label, protected from moisture and light. Stock solutions prepared in dimethyl sulfoxide should be held in sealed, solvent-compatible vials and dispensed as small aliquots to avoid repeated freeze-thaw cycles and unnecessary exposure of the bulk material. Handle the solid in a fume hood or suitably ventilated area, weighing it carefully to limit dust generation. Wear gloves, safety glasses, and a laboratory coat, and avoid direct skin or eye contact. As this material is intended for research use only and not for therapeutic or diagnostic application, it should be handled by trained personnel, labelled clearly with compound name and preparation date, and disposed of as chemical waste in accordance with institutional procedures and the manufacturer's safety data sheet.

—